Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment. Moreover, it is estimated that in 2015, there were 2.1 million diagnosed cases of UC in U.S., Japan, and five major European countries namely Germany, France, Italy, Spain, and UK. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

The major factors that drive the growth of the global ulcerative colitis market are increasing number of ulcerative colitis patients, new drug formulations by key players, and increasing investments by government and non-government organizations towards research in biologics. However, patent expiry and availability of alternative surgery option for UC treatment restricts the market growth. Conversely, untapped economies are expected to provide lucrative growth opportunities to the market.

The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables. Regionally, the market is analyzed in North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS:

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global ulcerative colitis market.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities across the geographies.
This report entails the detailed quantitative analysis of the current market and estimations from 2016 to 2023 to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise ulcerative colitis market conditions are comprehensively analyzed in the report.

KEY MARKET SEGMENTS

By Disease Type

Mild Ulcerative Colitis
Moderate Ulcerative Colitis
Severe Ulcerative Colitis

By Molecule Type

Biologics
Small Molecules

By Route of Administration

Oral
Injectables

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
South Korea
India
Rest of Asia-Pacific
LAMEA
Saudi Arabia
South Africa
Israel
Rest of LAMEA